2021 Asia-Pacific League of Associations for Rheumatology clinical practice guideline for treatment of gout

doi:10.1111/1756-185X.14266

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/23380

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/23380

Title:	2021 Asia-Pacific League of Associations for Rheumatology clinical practice guideline for treatment of gout
Authors:	Lorenzo, JPP;Sollano, MHMZ;Salido, EO;Li-Yu, J;Tankeh-Torres, SA;Manuaba, IARW;Rahman, MM;Paul, BJ;Mok, MY;De Silva, M;Padhan, P;Lim, AL;Marcial, M;Vicera, JJ;Haq, SA;Salman, S;Liyanage, CK;Keen, HI;Kuang, CY;Wei, JCC;Hellmi, RY;Chan, CE;Louthrenoo, W
Keywords:	acute gout;chronic tophaceous gout;clinical practice guidelines;gout;non-pharmacologic;prophylaxis;urate-lowering therapy
Date:	2021
Issue Date:	2022-08-05T09:36:20Z (UTC)
Publisher:	WILEY
ISSN:	1756-1841
Abstract:	Background Gout is the most prevalent inflammatory arthritis in the Asia-Pacific region and worldwide. This clinical practice guideline (CPG) aims to provide recommendations based on systematically obtained evidence and values and preferences tailored to the unique needs of patients with gout and hyperuricemia in Asia, Australasia, and the Middle East. The target users of these guidelines are general practitioners and specialists, including rheumatologists, in these regions. Methods Relevant clinical questions were formulated by the Steering Committee. Systematic reviews of evidence were done, and certainty of evidence was assessed using Grading of Recommendations Assessment, Development and Evaluation methodology. A multi-sectoral consensus panel formulated the final recommendations. Results The Asia-Pacific League of Associations for Rheumatology Task Force developed this CPG for treatment of gout with 3 overarching principles and 22 recommendation statements that covered the treatment of asymptomatic hyperuricemia (2 statements), treatment of acute gout (4 statements), prophylaxis against gout flare when initiating urate-lowering therapy (3 statements), urate-lowering therapy (3 statements), treatment of chronic tophaceous gout (2 statements), treatment of complicated gout and non-responders (2 statements), treatment of gout with moderate to severe renal impairment (1 statement), and non-pharmacologic interventions (5 statements). Conclusion Recommendations for clinically relevant scenarios in the management of gout were formulated to guide physicians in administering individualized care.
URI:	http://dx.doi.org/10.1111/1756-185X.14266 https://www.webofscience.com/wos/woscc/full-record/WOS:000731797000001 https://ir.csmu.edu.tw:8080/handle/310902500/23380
Relation:	INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES ,2022,v25,issue 1, P7-20
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	264	View/Open

Loading...